Krause P - Search Results

1

COVID-19 vaccine trials should seek worthwhile efficacy.

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R; World Health Organization Solidarity Vaccines Trial Expert Group. Krause P, et al. Lancet. 2020 Sep 12;396(10253):741-743. doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27. Lancet. 2020. PMID: 32861315 Free PMC article. No abstract available.

2

Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.

Krause PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM; WHO Ad Hoc Clinical Trial Expert Group. Krause PR, et al. Lancet. 2020 Nov 21;396(10263):1611-1613. doi: 10.1016/S0140-6736(20)32259-5. Epub 2020 Oct 27. Lancet. 2020. PMID: 33125926 Free PMC article. No abstract available.

3

A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture.

Lewis AM Jr, Krause P, Peden K. Lewis AM Jr, et al. Among authors: krause p. Dev Biol (Basel). 2001;106:513-35. Dev Biol (Basel). 2001. PMID: 11761266 No abstract available.

4

Adventitious agents and vaccines.

Krause PR. Krause PR. Emerg Infect Dis. 2001;7(3 Suppl):562. doi: 10.3201/eid0707.017735. Emerg Infect Dis. 2001. PMID: 11485673 Free PMC article. No abstract available.

5

Detection of enteric adenoviruses by dot-blot hybridization using a molecularly cloned viral DNA probe.

Takiff HE, Seidlin M, Krause P, Rooney J, Brandt C, Rodriguez W, Yolken R, Straus SE. Takiff HE, et al. Among authors: krause p. J Med Virol. 1985 Jun;16(2):107-18. doi: 10.1002/jmv.1890160203. J Med Virol. 1985. PMID: 2989418

6

Safety of viral DNA in biological products.

Krause PR, Lewis AM Jr. Krause PR, et al. Biologicals. 1998 Dec;26(4):317-20. doi: 10.1006/biol.1998.0161. Biologicals. 1998. PMID: 10403035

7

Conceptual and experimental approaches to address product safety issues raised by novel cell substrates.

Krause PR. Krause PR. Dev Biol (Basel). 2001;106:45-8; discussion 49-50. Dev Biol (Basel). 2001. PMID: 11761261

8

Live oral poliovirus vaccines do not contain detectable simian virus 40 (SV40) DNA.

Sierra-Honigmann A, Krause PR. Sierra-Honigmann A, et al. Among authors: krause pr. Biologicals. 2000 Mar;28(1):1-4. doi: 10.1006/biol.1999.0233. Biologicals. 2000. PMID: 10799049

9

Goals of stability evaluation throughout the vaccine life cycle.

Krause PR. Krause PR. Biologicals. 2009 Nov;37(6):369-78; discussion 421-3. doi: 10.1016/j.biologicals.2009.08.015. Epub 2009 Sep 22. Biologicals. 2009. PMID: 19775911 Review.

10

Pharmacoepidemiologic implications of erroneous varicella vaccinations in pregnancy through confusion with Varicella zoster immune globulin.

Wise RP, Braun MM, Seward JF, Mootrey GT, Shields KE, Salive ME, Krause PR. Wise RP, et al. Among authors: krause pr. Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):651-4. doi: 10.1002/pds.749. Pharmacoepidemiol Drug Saf. 2002. PMID: 12512240

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

701 results

Search Page